Development
Takeda Pharmaceutical Company Limited
TAK
$15.30
-$0.22-1.42%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -15.23% | -174.38% | -19.65% | 340.73% | 66.22% |
| Total Depreciation and Amortization | 1.02% | 4.08% | 2.27% | -3.57% | -3.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -21.40% | -- |
| Total Other Non-Cash Items | -39.16% | 74.44% | -7.28% | -166.26% | -52.97% |
| Change in Net Operating Assets | -409.10% | 555.87% | 10.31% | -29.52% | -53.78% |
| Cash from Operations | -63.02% | -13.95% | 3.53% | -31.33% | -12.27% |
| Capital Expenditure | -34.38% | -23.51% | -2.98% | 11.71% | 0.36% |
| Sale of Property, Plant, and Equipment | 1,599.92% | 12,536.51% | -69.49% | -44.79% | -159.58% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -73.18% | -- |
| Other Investing Activities | -105.79% | -1,563.16% | -296.34% | -1,962.99% | 46.68% |
| Cash from Investing | -53.98% | -112.89% | -165.62% | -1,402.01% | 45.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 63.75% | -1,358.81% | -197.97% | 53.49% | -30.91% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 91.36% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.38% | 22.16% | 4.24% | 14.01% | 20.90% |
| Other Financing Activities | 17.01% | 185.00% | -5.64% | -8.14% | -21.97% |
| Cash from Financing | 78.53% | -159.23% | 74.72% | 97.62% | -108.61% |
| Foreign Exchange rate Adjustments | 68.94% | -62.63% | -38.04% | -100.97% | -225.61% |
| Miscellaneous Cash Flow Adjustments | 291.55% | -- | -194.81% | -- | -- |
| Net Change in Cash | 74.90% | -98.95% | -0.62% | -206.21% | -178.21% |